6-K
Radiopharm Theranostics Ltd (RADX)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of November 2025
Commission File Number: 001-41621
RADIOPHARM THERANOSTICS LIMITED
(Name of Registrant)
Level 3, 62 Lygon Street, Carlton South,Victoria, 3053, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
RADIOPHARM THERANOSTICS LIMITED
EXPLANATORY NOTE
Radiopharm Theranostics Limited (the “Company”) published two announcements (the “Public Notice”) to the Australian Securities Exchange on November 25, 2025 titled:
| “Final Director’s Interest Notice - LA” |
|---|
| “Final Director’s Interest Notice - PH” |
A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.
This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
1
EXHIBITS
| Exhibit <br><br>Number | Description |
|---|---|
| 99.1 | Final Director’s Interest Notice - LA |
| 99.2 | Final Director’s Interest Notice - PH |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| RADIOPHARM THERANOSTICS LIMITED | ||
|---|---|---|
| Date: November 25, 2025 | By: | /s/ Phillip Hains |
| Phillip Hains | ||
| Company Secretary |
3
Exhibit 99.1
Appendix3Z
FinalDirector’s Interest Notice
Rule 3.19A.3
Appendix 3Z
Final Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced 30/9/2001.
| Name of entity: Radiopharm Theranostics Limited (ASX: RAD) |
|---|
| ABN: 57 647 877 889 |
We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of director | Leila Alland |
|---|---|
| Date of last notice | 18 December 2024 |
| Date that director ceased to be director | 20 November 2025 |
Part 1 – Director’s relevant interests in securities of which the director is the registered holder
In the caseof a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Number & class of securities<br><br> <br><br><br> <br>1,071,740 Fully<br> Paid Ordinary Shares<br><br> <br>10,400,002<br> Unlisted Options | |
|---|---|
| + See chapter 19 for defined terms. | |
| --- | --- |
| 11/3/2002 | |
| Appendix 3Z Page 1 |
Appendix3Z
Final Director’s Interest Notice
Part 2 – Director’s relevant interests in securities of which the director is not the registered holder
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
In the caseof a trust, this includes interests in the trust made available by the responsible entity of the trust
| Name of holder & nature of interest<br><br> <br>Note: Provide details of the circumstances giving<br> rise to the relevant interest<br><br> <br><br><br> <br><br><br> <br><br><br> <br><br><br> <br><br><br> <br><br><br> <br><br><br> <br><br><br> <br><br><br> <br> | Number & class of securities<br><br> <br><br><br> <br><br><br> <br>Nil. |
|---|
Part 3 –Director’s interests in contracts
| Detail of contract | N/A |
|---|---|
| Nature of interest | N/A |
| Name of registered holder (if issued securities) **** | N/A |
| No. and class of securitiesto which interest relates | N/A |
| + See chapter 19 for defined terms. | |
| --- | --- |
| Appendix 3Z Page 2 | 11/3/2002 |
Exhibit 99.2
Appendix 3Z
Final Director’s Interest Notice
Rule 3.19A.3
Appendix 3Z
Final Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced 30/9/2001.
| Name of entity: Radiopharm Theranostics Limited (ASX: RAD) |
|---|
| ABN: 57 647 877 889 |
We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of director | Phillip Hains |
|---|---|
| Date of last notice | 18 December 2024 |
| Date that director ceased to be director | 20 November 2025 |
Part 1 – Director’s relevant interests in securities of which the director is the registered holder
In the caseof a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Number & class of securities<br><br> <br><br><br> <br>9,900,002 Unlisted<br> Options | |
|---|---|
| + See chapter 19 for defined terms. | |
| --- | --- |
| 11/3/2002 | |
| Appendix 3Z Page 1 |
Appendix 3Z
Final Director’s Interest Notice
Part 2 – Director’s relevant interests in securities of which the director is not the registered holder
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
In the caseof a trust, this includes interests in the trust made available by the responsible entity of the trust
| Name of holder & nature of interest<br><br> <br>Note: Provide details of the circumstances giving<br> rise to the relevant interest<br><br> <br><br><br> <br><br><br> <br>Director related entity<br><br> <br><br><br> <br><br><br> <br><br><br> <br><br><br> <br><br><br> <br><br><br> <br> | Number & class of securities<br><br> <br><br><br> <br><br><br> <br><br><br> <br>15,956,632<br> Fully Paid Ordinary Shares<br><br> <br>6,933,560 Unlisted<br> Options |
|---|
Part 3 –Director’s interests in contracts
| Detail of contract | N/A |
|---|---|
| Nature of interest **** **** | N/A |
| Name of registered holder (if issued securities) **** | N/A |
| No. and class of securities to which interest relates **** **** | N/A |
| + See chapter 19 for defined terms. | |
| --- | --- |
| Appendix 3Z Page 2 | 11/3/2002 |